Aubagio® delays onset of clinically definite MS, study
Aubagio® delays onset of clinically definite MS, study
Genzyme, a Sanofi company, announced today positive top-line results from the TOPIC trial for Aubagio (teriflunomide). The trial was designed to assess whether early initiation of Aubagio (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS)..... Read More - http://www.ms-uk.org/index.cfm/aubagio
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1478 Views
-
Last post by NHE
-
- 0 Replies
- 813 Views
-
Last post by NHE
-
- 0 Replies
- 2260 Views
-
Last post by frodo
-
- 0 Replies
- 1097 Views
-
Last post by NHE
-
- 1 Replies
- 1041 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1340 Views
-
Last post by frodo
-
- 0 Replies
- 1573 Views
-
Last post by NHE
-
- 0 Replies
- 2053 Views
-
Last post by vesta
-
- 0 Replies
- 1626 Views
-
Last post by frodo